Economic Challenges and Possible Policy Actions to Advance Stratified medicine

• Trusheim MR , BerndtER, DouglasFL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Disc.6 , 287–293 (2007).
   PubMed Web of Science ®Google Scholar
• Frueh FW , AmurS, MummaneniP et al. Pharmacogenic biomarker information in drug labels approved by the United States Food and Drug Administration: prevalence of related drug use. Pharmacotherapy 28(8) , 992–998 (2008).
   PubMed Web of Science ®Google Scholar
• Woodcock J . The prospects for ‘personalized medicine‘ in drug development and drug therapy. Clin. Pharmacol. Ther.81 , 164–169 (2007).
   PubMed Web of Science ®Google Scholar
• Trusheim MR , BurgessB, Xinghua Hu S et al. Quantifying stratified medicine success factors: a multi-stakeholder perspective. Nat. Rev. Drug Disc.10(11) , 817–833 (2011).
   PubMed Web of Science ®Google Scholar
• Institute of Medicine. Policy Issues in the Development of Personalized Medicine in Oncology: Workshop Summary. The National Academies Press Washington, DC, USA (2010).
   Google Scholar
• Pegram MD , PaulettiG, SlamonDJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res. Treat.52(1–3) , 65–77 (1998).
   PubMed Web of Science ®Google Scholar
• Amodol RG , WolfM, FreemanD et al. Analysis of KRAS mutations in patients with metastatic colorectal cancer receiving panitumumab monotherapy. Eur. J. Cancer Suppl. 5 , 8 (2007).
   Google Scholar
• DiMasi JA , GrabowskiHG. Economics of new oncology drug development. J. Clin. Oncol.25(2) , 209–216 (2007).
   PubMed Web of Science ®Google Scholar
• US Cancer Statistics Working Group. United States Cancer Statistics: 1999–2004 Incidence and Mortality Web-Based Report. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, GA, USA (2007).
   Google Scholar
• Fojo T , GradyC. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J. Natl Cancer Inst.101 , 1044–1048 (2009).
   PubMed Web of Science ®Google Scholar
• Chiang A , MillionRP. Personalized medicine in oncology: next generation. Nat. Rev. Drug Disc.10(12) , 895–896 (2011).
   PubMed Web of Science ®Google Scholar
• Pollack A . Approval for drug that treats melanoma. New York Times, 25 March (2011).
   Google Scholar
• Woelderink A , IbarretaD, HopkinsMM and Rodriguez-Cerezo E. The current clinical practice of pharmacogenetic testing in Europe: TPMT and HER2 as case studies. Pharmacogenomics J.6 , 3–7 (2006).
   PubMed Web of Science ®Google Scholar
• Loupakis F , VasileE, SantiniD, MasiG, FalconeA, GrazianoF. EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach. Pharmacogenomics9(1) , 55–69 (2008).
   PubMed Web of Science ®Google Scholar
• Radack DV . GATT brings major changes in U.S. patent law. JOM47(5) , 79 (1995).
   Google Scholar
• Gottlieb S . The FDA is evading the law. Wall Street Journal, 23 December (2010).
   Google Scholar
• Ridley DA , GrabowskiHG, MoeJ. Developing drugs for developing countries. Health Affairs25(2) , 313–324 (2006).
   PubMed Web of Science ®Google Scholar
• Berndt ER , GottschalkAHB, StrobeckMW. Opportunities for improving the drug development process: results from a survey of industry and the FDA. In: Innovation Policy and the Economy. Jaffe AB, Lerner J, Stern SM (Eds). MIT Press for the National Bureau of Economic Research, MA, USA, 91–121 (2006).
   Google Scholar
• Woosley RL , RiceG. A new system for moving drugs to market. Issues Sci. Technol.21(2) , 63–68 (2005).
   Web of Science ®Google Scholar
• Eichler HG , OyeK, BairdLG et al. Adaptive licensing: taking the next step in the evolution of drug approval. Clin. Pharmacol. Ther. 91(3) , 426–437 (2012).
   PubMed Web of Science ®Google Scholar
• Chabner BA . Early accelerated approval for highly targeted cancer drugs. N. Engl. J. Med.364(12) , 1087–1089 (2011).
   PubMed Web of Science ®Google Scholar
• McClellan M , BennerJ, SchliskyR et al. An accelerated pathway for targeted cancer therapies. Nature Rev. Drug Disc. 10(2) , 79–80 (2011).
   PubMed Web of Science ®Google Scholar
• Fox FL . NCATS launches. Nat. Biotechnol.30 , 204 (2012).
   PubMed Web of Science ®Google Scholar
• Berndt ER , HurvitzJA. Vaccine advance – purchase agreements for low-income countries: practical issues. Health Affairs24(3) , 653–665 (2005).
   Web of Science ®Google Scholar
• Kremer M and Williams H. Incentivizing innovation: adding to the tool kit. In: Innovation Policy and the Economy. Lerner J, Stern SM (Eds). MIT Press for the National Bureau of Economic Research, MA, USA, 1–17 (2010).
   Google Scholar
• DiMasi JA , HansenRW, GrabowskiHG. The price of innovation: new estimates of drug development costs. J. Health Econ.22(2) , 141–185 (2003).
   Google Scholar
• DiMasi JA , HansenRW, GrabowskiHG, LasagnaL. Research and development costs for new drugs by therapeutic category: a study of the US pharmaceutical industry. Pharmacoeconomics7 , 152–160 (1995).
   PubMed Web of Science ®Google Scholar
• DiMasi JA , GrabowskiHG. The cost of biopharmaceutical R&D: is biotech different? Manage. Decis. Econ.28 , 469–479 (2007).
   Google Scholar
• Adams CP , BrantnerVV. Estimating the cost of new drug development: is it really $802 million? Health Affairs25(2) , 420–428 (2006).
   PubMed Web of Science ®Google Scholar
• Walker I , NewellH. Do molecularly targeted agents in oncology have reduced attrition rates? Nat. Rev. Drug Disc.8(1) , 15–16 (2009).
   PubMed Web of Science ®Google Scholar
• Abrantes-Metz RM , AdamsCP, MetzAD. Pharmaceutical development phases: a duration analysis. J. Pharmaceutical Finance Econ. Policy14(4) , 19–42 (2005).
   Google Scholar
• Stern D , ReissmanD. Specialty pharmacy cost management strategies of private health care payers. J. Manag. Care Pharm.12(9) , 736–744 (2006).
   PubMed Web of Science ®Google Scholar

▪ Websites

• US FDA clears Abbott‘s companion Dx for Pfizer‘s NSCLC Drug. GenomeWeb Daily News. 29 August 2011. www.genomeweb.com/mdx/fda-clears-abbotts-companion-dx-pfizers-nsclc-drug (Accessed 6January2012)
   Google Scholar
• Jefferson E. US FDA approves Xalkori with companion diagnostic for a type of late-stage lung cancer. FDA News Release. 26 August 2011. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm269856.htm (Accessed 6January2012)
   Google Scholar
• McHale D. Current experience with stratified medicines & current drugs in development. Presented at: Fifth Forum of the Ministerial Industry Strategy Group (MISG) UK MHRA. 9 October 2009. www.mhra.gov.uk/home/groups/es-policy/documents/websiteresources/con065595.pdf (Accessed 17June2011)
   Google Scholar
• US Department of Health and Human Services, US FDA. FY 2011 innovative drug approvals. www.fda.gov/downloads/aboutfda/reportsmanualsforms/reports/ucm278358.pdf (Accessed 1February2012)
   Google Scholar
• American Cancer Society. Cancer Facts and Figures 2010. American Cancer Society No. 500810. 2. (2010). www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-and-figures-2010 (Accessed 17June2011)
   Google Scholar
• Associated Press. $93,000 cancer drug: how much is a life worth? Boston Herald 27 September 2010.http://news.bostonherald.com/business/healthcare/view/2010092793000_cancer_drug_how_much_is_a_life_worth/srvc=home&position=recent (Accessed 17June2011)
   Google Scholar
• Mucahy N. Time to consider cost in evaluating cancer drugs in United States? Medscape News Today. www.medscape.com/viewarticle/705689 (Accessed 14June2011)
   Google Scholar
• Melanoma (stage III or IV) – ipilimumab: appraisal consultation document. NHS NICE 14 October 2011.http://guidance.nice.org.uk/TA/WaveCRS2/48/Consultation/DraftGuidance (Accessed 6January2012)
   Google Scholar
• Kobelt G et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the USA. SSE/EFI Working Paper Series in Economics and Finance 594 (Dec 2004).http://swopec.hhs.se/hastef/papers/hastef0594.pdf (Accessed 17June2011)
   Google Scholar
• Recap by Deloitte. www.recap.com (Accessed 11February2011)
   Google Scholar
• Albainy-Jenei S. Three-year market exclusivity extension for a new indication of a drug. Patent Baristas 7 March 2006. www.patentbaristas.com/archives/2006/03/07/three-year-market-exclusivity-extension-for-a-new-indication-of-a-drug/ (Accessed 17June2011).
   Google Scholar
• US FDA. Frequently asked questions on pediatric exclusivity (505a), the pediatric ‘rule‘, and their interaction. www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm077915.htm (Accessed 17June2011)
   Google Scholar
• US Patent Office. Manual of patent examining procedures (MPEP) 2755.02 Interim Extension of Patent Term Before Product Approval - 2700 Patent Terms and Extensions. USPTO Edition 8(E8) August 2001, last revision July 2010. www.uspto.gov/web/offices/pac/mpep/documents/2700_2755_02.htm (Accessed 17June2011)
   Google Scholar
• Copyright Term Extension Act of 1998, S.505, 27 January 1998. www.copyright.gov/legislation/s505.pdf (Accessed 18December2010)
   Google Scholar
• US FDA. CFR-Code of Federal Regulations Title 21. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=314&showFR=1&subpartNode=21:5.0.1.1.4.8 (Accessed 17June2011).
   Google Scholar
• US FDA. US FDA approves coartem tablets to treat malaria. News release, 8 April 2009. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm149559.htm (Accessed 17June2011)
   Google Scholar
• Advance Market Commitments for Vaccines. The pneumococcal AMC: ready to save lives. www.vaccineamc.org (Accessed 17June2011)
   Google Scholar
• Advance Market Commitments for Vaccines. Update: GAVI Partners Fulfill Promise To Fight Pneumococcal Disease. News release 12 June 2009. www.vaccineamc.org/updatejun_09.html (Accessed 17June2011)
   Google Scholar
• Advance Market Commitments for Vaccines. Update: GSK vaccine receives AMC approval by Independent Assessment Committee. News release 7 May 2010. www.vaccineamc.org/updatemay7_10.html (Accessed 17June2011)
   Google Scholar
• Advance Market Commitments for Vaccines. Pfizer vaccine receives AMC approval by Independent Assessment Committee. Press release, 10 September 2010. www.vaccineamc.org/updatesept10_10.html (Accessed 17June2011)
   Google Scholar
• Glassman A. Break out the champagne! The AMC delivers vaccine. Center for Global Development, 13 December 2010.http://blogs.cgdev.org/globalhealth/2010/12/break-out-the-champagne-the-amc-delivers-vaccines.phpl (Accessed 17June2011)
   Google Scholar
• Nord J, Lynn K. Pawlenty approves ‘angel‘ tax credit bill. Mndaily.com 4 April 2010. www.mndaily.com/2010/04/04/pawlenty-approves-%E2%80%98angel%E2%80%99-tax-credit-bill (Accessed 17June2011)
   Google Scholar
• Lee J. President Obama signs small business jobs act–learn what‘s in it. 2010 September 27 In: The White House blog. www.whitehouse.gov/blog/2010/09/27/president-obama-signs-small-business-jobs-act-learn-whats-it (Accessed 17June2011)
   Google Scholar
• Sterk J. Assessing the impact of tumor evolution on oncology drug development and commercialization. Unpublished SM thesis, Harvard-MIT Division of Health Sciences and Technology, MA, USA (June 2011).http://dspace.mit.edu/handle/1721.1/65523 (Accessed 9January2012)
   Google Scholar
• Lucarelli C, Nicholson S. A quality-adjusted price index for colorectal cancer drugs. NBER Working Paper No. 15174 (July 2009). www.nber.org/papers/w15174 (Accessed 6May2012)
   Google Scholar
• Yee CM. New model aims to put brakes on rising cost of cancer care. Minneapolis Star Tribune October 19, 2010. www.startribune.com/business/105312318.html?elr=KArksUUUoDEy3LGDiO7ai (Accessed 17June2011)
   Google Scholar
• Petttypiece S. Bristol-Myers Sprycel Drug Beats Gleevec in Leukemia Patients, Study Says. Bloomberg News (5 June 2010). www.bloomberg.com/news/2010–2006–05/bristol-myers-sprycel-drug-beats-gleevec-in-leukemia-patients-study-says.html (Accessed 17June2011)
   Google Scholar
• Sabir SA. The economic and ethical considerations and implications of the stratification of future oncology therapeutics. Unpublished SM thesis, Harvard-MIT Division of Health Sciences and Technology, MA, USA (June 2009).http://hdl.handle.net/1721.1/54674 (Accessed 17June2011)
   Google Scholar
• Austin DH, Kyle J, Moore D. Research and development in the pharmaceutical industry. Congressional Budget Office Pub No. 2589 (October 2006). www.cbo.gov/sites/default/files/cbofiles/ftpdocs/76xx/doc7615/10-02-drugr-d.pdf (Accessed 6May2012)
   Google Scholar
• Office of Technology Assessment. Pharmaceutical R&D: costs, risks and rewards, OTA-H-522 (February 1993). www.fas.org/ota/reports/9336.pdf (Accessed 6May2012)
   Google Scholar
• PriceWaterhouseCoopers MoneyTree™ report. www.pwcmoneytree.com (Accessed 11February2011)
   Google Scholar